Adavosertib for Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications, especially those that affect the CYP3A4 enzyme, at least 2 weeks before starting the study and throughout the trial. Herbal supplements like St. John's wort and certain cholesterol medications are also prohibited.
What makes the drug Adavosertib unique for cancer treatment?
Adavosertib is unique because it is the first small-molecule inhibitor of WEE1 kinase, which plays a role in controlling cell division. This drug is particularly promising for cancers with specific genetic mutations, like RAS and TP53, as it targets the DNA replication process that these mutations affect.12345
What is the purpose of this trial?
This trial studies how well adavosertib works in patients with advanced or metastatic solid tumors that lack the SETD2 gene. Adavosertib may help stop tumor growth by blocking enzymes needed for cancer cells to grow. Adavosertib is a first-in-class, small-molecule reversible inhibitor of WEE1 kinase, previously shown to have clinical activity in various cancers.
Research Team
Rahul R Aggarwal
Principal Investigator
Yale University Cancer Center LAO
Eligibility Criteria
This trial is for adults with advanced solid tumors that have spread and have a SETD2 mutation. They must have tried at least one therapy, be able to swallow pills, not be pregnant or breastfeeding, use contraception if fertile, and meet certain health criteria like specific blood cell counts.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive adavosertib orally once daily on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Adavosertib
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor